Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to ...

The data published in NEJM highlight the positive Phase 3 VALIANT results at Week 26, which were consistent across adolescent and adult patients with C3G and primary IC-MPGN, including patients with ...

Researchers are urging collaborators to think about the best structural resolution for their formulation models.

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF ...

Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.

Pivotal Phase 3 ECLIPSE study demonstrated atogepant is superior to placebo for achieving pain freedom at two hours after treatment of the first migraine ...

Accord BioPharma Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that Express Scripts, one of ...

Following the success of training programmes of public drug testing labs in 10 states in the country, the Indian Pharmacopoeia Commission (IPC) is all set to launch pan-India capacity building ...

India’s drug regulator has sounded a fresh alarm over toxic solvent contamination in paediatric syrups, prompting urgent ...

Sudeep Pharma Limited IPO closed for subscription on Tuesday, November 25. The issue is structured as a book-building IPO ...

Sudeep Pharma is set to list today after raising Rs 895 crore through a mix of fresh shares and an offer for sale. The grey ...